ArticleThe Journal of antimicrobial chemotherapy2021
Invasive infections with Purpureocillium lilacinum: clinical characteristics and outcome of 101 cases from FungiScope® and the literature.
Article in The Journal of antimicrobial chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 41 citations in OpenAlex.
- Purpureocillium lilacinum and Pochonia chlamydosporia as biocontrol agents: a comparative review of efficacy, ecology, and integrated application.Archives of microbiology · 2026Review
- Establishment of epidemiological cutoff values againstJournal of clinical microbiology · 2026Article
- The Brief Case: Recalcitrant cutaneous and subcutaneous knee infection caused byJournal of clinical microbiology · 2026Review
- Article
- Cutaneous and Subcutaneous Hyalohyphomycosis Caused by Purpureocillium Lilacinum in a Tertiary Referral Hospital in Central China.The Journal of dermatology · 2026Article
- Therapeutic Failure in Invasive Fungal Infections: Beyond Antifungal Resistance-A Narrative Review.Journal of fungi (Basel, Switzerland) · 2026Review
- 30 years in service, 1996-2026: Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).Annals of hematology · 2026Review
- First clinical isolation ofOxford medical case reports · 2026Article
- Manogepix demonstrates potentAntimicrobial agents and chemotherapy · 2026Article
- Article
- Voriconazole-resistantMedical mycology case reports · 2026Article
- A hospital-based retrospective study of hospitalizations with hyalohyphomycosis and phaeohyphomycosis in the United States.Lancet regional health. Americas · 2026Article
- Left-Sided Weakness in a Kidney Transplant Recipient.Kidney360 · 2026Article
- Bursting at the Seams.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Pseudo-Outbreak of Purpureocillium lilacinum Skin Infections at a Dermatology Clinic - Washington, 2024.MMWR. Morbidity and mortality weekly report · 2026Article
- Purpureocillium lilacinum Keratitis Outbreak Associated with an Ophthalmology Clinic - New York City, 2024.MMWR. Morbidity and mortality weekly report · 2026Article
- Humidifier lung diagnosed by integrating environmental assessment and inhalation provocation testing: a case withRespiratory medicine case reports · 2026Article
- Clinical Manifestations, Antifungal Susceptibilities, and Outcome of Ocular Infections Caused byMicroorganisms · 2025Article
- Article
- AggressiveJournal of fungi (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 11 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo provide a basis for clinical management decisions in Purpureocillium lilacinum infection.
methodsUnpublished cases of invasive P. lilacinum infection from the FungiScope® registry and all cases reported in the literature were analysed.
resultsWe identified 101 cases with invasive P. lilacinum infection. Main predisposing factors were haematological and oncological diseases in 31 cases (30.7%), steroid treatment in 27 cases (26.7%), solid organ transplant in 26 cases (25.7%), and diabetes mellitus in 19 cases (18.8%). The most prevalent infection sites were skin (n = 37/101, 36.6%) and lungs (n = 26/101, 25.7%). Dissemination occurred in 22 cases (21.8%). Pain and fever were the most frequent symptoms (n = 40/101, 39.6% and n = 34/101, 33.7%, respectively). Diagnosis was established by culture in 98 cases (97.0%). P. lilacinum caused breakthrough infection in 10 patients (9.9%). Clinical isolates were frequently resistant to amphotericin B, whereas posaconazole and voriconazole showed good in vitro activity. Susceptibility to echinocandins varied considerably. Systemic antifungal treatment was administered in 90 patients (89.1%). Frequently employed antifungals were voriconazole in 51 (56.7%) and itraconazole in 26 patients (28.9%). Amphotericin B treatment was significantly associated with high mortality rates (n = 13/33, 39.4%, P = <0.001). Overall mortality was 21.8% (n = 22/101) and death was attributed to P. lilacinum infection in 45.5% (n = 10/22).
conclusionsP. lilacinum mainly presents as soft-tissue, pulmonary or disseminated infection in immunocompromised patients. Owing to intrinsic resistance, accurate species identification and susceptibility testing are vital. Outcome is better in patients treated with triazoles compared with amphotericin B formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.